Disclosures: Fatima DAHBOUL: Nothing to Disclose, JIHAN SUN: Nothing to Disclose, Benjamin Buchard: Nothing to Disclose, Delphine Weil-Verhoeven: Nothing to Disclose, Vincent Di Martino: Nothing to Disclose, Aicha Demidem: Nothing to Disclose, Armand Abergel: Nothing to Disclose 1875 RADIOMICS-BASED PREDICTION OF HCC RESPONSE TO ATEZOLIZUMAB/BEVACIZUMAB Isaac Israel Rodriguez Salazar 1 Andreas Teufel 1 Abhinay Vellala 1 Timo Itzel 1 Jimmy Daza 1 Michael Vcha 1 Manuel Debic 2 De-Hua Chang 3 Michael Dill 2 Max Seidensticker 4 Gerd Oswald Stefan Schnberg 1 Lukas Mller 5 Julia Mayerle 4 Stefan Munker 4 Peter Galle 5 Arndt Weinmann 5 Dietmar Tamandl 6 Matthias Pinter 6 Marino Venerito 7 Matthias Ebert 1 Matthias Froelich 1 Maciej Pech 7 Friedrich Sinner 7 Bernhard Scheiner 6 , 1 Medical Faculty Mannheim, 2 Medical Faculty Heidelberg, 3 Cantonal Hospital of Lucerne, 4 LMU Munich, 5 University Medical Center Mainz, 6 Medical Faculty Vienna, 7 Magdeburg University Background: Atezolizumab/ bevacizumab has emerged as a breakthrough therapy for advanced hepatocellular carcinoma (HCC)
It's worth noting that a good healthcare insurance provider would cover diagnostic tests including a vitamin B12 test under their policy
Xanthohumol Alleviates Inflammatory Bowel Disease-Associated Osteoporosis via Regulating Gut Microbial Metabolites
Oleksiak MF, Churchill GA, Crawford DL
First, GPX4 reduces the toxic lipid peroxides to non-toxic lipid alcohols by oxidizing its active site, selenol (Se-H), to selenenic acid (Se-OH)
Chronic stress can exacerbate inflammation and contribute to various health issues
